國藥現代(600420.SH):2024年淨利潤同比增長56.62% 擬10股派2元
格隆匯3月27日丨國藥現代(600420.SH)公佈2024年度報告,報告期內,公司實現營業收入109.38億元,同比降低9.38%;實現歸屬於上市公司股東的淨利潤10.84億元,同比增長56.62%;歸屬於上市公司股東的扣除非經常性損益的淨利潤10.43億元,同比增長52.72%;全年綜合毛利率39.24%,較上年同期提高0.91個百分點。同時公司堅定不移實施“創新驅動”發展戰略,緊緊圍繞中長期戰略發展目標,加大研發投入力度,加快研發成果轉化,2024年公司研發投入6.75億元,佔營業收入的6.17%,比上年提高0.41個百分點。向全體股東每10股派發現金紅利2元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.